Back Zuranolon German Zuranoloon Estonian זורנולון HE ズラノロン Japanese Zuranolona Portuguese

Zuranolone

Zuranolone
Clinical data
Pronunciation/zʊˈrænəloʊn/
zuu-RAN-ə-lohn
Trade namesZurzuvae
Other namesSAGE-217; S-812217; SGE-797; BIIB-125
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		By mouth
Drug classNeurosteroid; GABAA receptor positive allosteric modulator
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding99.5%[2][unreliable medical source?]
MetabolismCYP3A4[2][unreliable medical source?]
Elimination half-life16–23 hours[3][4]
Identifiers
  • 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.271.331 Edit this at Wikidata
Chemical and physical data
FormulaC25H35N3O2
Molar mass409.574 g·mol−1
3D model (JSmol)
  • O=C(CN1N=CC(C#N)=C1)[C@H]2CC[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@](C)(O)CC[C@]5([H])[C@@]4([H])CC[C@@]32C
  • InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
  • Key:HARRKNSQXBRBGZ-GVKWWOCJSA-N

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression.[5][6] It is taken by mouth.[5]

The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.[5][6] An orally active inhibitory pregnane neurosteroid, zuranolone acts as a positive allosteric modulator of the GABAA receptor.[7][8][9]

Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023.[6] It was developed by Sage Therapeutics and Biogen.[10]

  1. ^ "Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV". Federal Register. 31 October 2023. Retrieved 5 March 2024.
  2. ^ a b "Zuranolone". DrugBank Online.
  3. ^ Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, et al. (2022). "GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacology & Therapeutics. 234: 108035. doi:10.1016/j.pharmthera.2021.108035. PMC 9787737. PMID 34793859. S2CID 244280839.
  4. ^ Faden J, Citrome L (2020). "Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?". Therapeutic Advances in Psychopharmacology. 10: 2045125320968658. doi:10.1177/2045125320968658. PMC 7656877. PMID 33224470.
  5. ^ a b c "Zurzuvae (zuranolone) capsules, for oral use, [controlled substance schedule pending]" (PDF). Archived (PDF) from the original on 5 August 2023. Retrieved 5 August 2023.
  6. ^ a b c Cite error: The named reference FDA PR 20230804 was invoked but never defined (see the help page).
  7. ^ "SAGE 217". AdisInsight. Archived from the original on 29 March 2019. Retrieved 10 February 2018.
  8. ^ Blanco MJ, La D, Coughlin Q, Newman CA, Griffin AM, Harrison BL, et al. (2018). "Breakthroughs in neuroactive steroid drug discovery". Bioorganic & Medicinal Chemistry Letters. 28 (2): 61–70. doi:10.1016/j.bmcl.2017.11.043. PMID 29223589.
  9. ^ Martinez Botella G, Salituro FG, Harrison BL, Beresis RT, Bai Z, Blanco MJ, et al. (2017). "Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor". Journal of Medicinal Chemistry. 60 (18): 7810–7819. doi:10.1021/acs.jmedchem.7b00846. PMID 28753313.
  10. ^ Saltzman J (4 August 2023). "FDA approves postpartum depression pill from two Cambridge drug firms". The Boston Globe. Archived from the original on 6 August 2023. Retrieved 5 August 2023.
From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Nelliwinne